FDA Bone Drug Study Offers New Pathway For Plaintiffs

Law360, New York (May 10, 2012, 10:44 PM EDT) -- A U.S. Food and Drug Administration analysis published Wednesday suggesting that the benefits of Merck & Co. Inc.'s Fosamax and other osteoporosis drugs may disappear over time will give plaintiffs suing the drugmakers over the products' purported side effects even more ammunition, attorneys say.

An article by FDA researchers in the New England Journal of Medicine questioned whether taking a class of drugs known as bisphosphonates beyond five years helps prevent fractures. Data from trials suggest patients might be able to discontinue use without sacrificing bone...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.